http://www.ContemporaryPediatrics.com/

Contemporary Pediatrics, 25115 Country Club Boulevard, North Olmsted, OH (2025)

08/05/2025

approval news:

The federal agency has approved fremanezumab‑vfrm (Ajovy; Teva Pharmaceuticals) injection for the preventive treatment of episodic migraine in pediatric patients age 6 years and older who weigh at least 45 kg (99 lb). This marks the first approval of a calcitonin gene‑related peptide (CGRP) ligand for migraine prevention in pediatrics, according to the FDA.

Full details: https://hubs.li/Q03BsnmC0

08/05/2025

In a new Q+A interview, Andrew Silverman, MD, MHS, Keith Van Haren MD, MD, and Molly Wilson-Murphy, MD, of Boston Children's Hospital and Harvard Medical School provide a deep dive into -associated acute necrotizing encephalopathy ( )

Read the full discussion here: https://hubs.li/Q03BpXPG0

08/05/2025

From our August Back-to-School issue:

The tail end of summer also serves as an excellent opportunity for parents to ensure their are caught up with all necessary and recommended before kicking off another year of learning, or perhaps, the child’s first year in the classroom.

In this article, Jesse Hackell, MD FAAP, and Lori Handy, MD MSCE of Children's Hospital of Philadelphia, speak to the importance of back-to-school vaccinations as well as handling vaccine hesitancy with families.

Read our full featured article from our August 2025 issue: https://www.contemporarypediatrics.com/view/aligning-vaccinations-with-the-start-of-a-new-school-year

08/04/2025

New data released today revealed a trend in the wrong direction for rates during the 2024-2025 school year, with a decrease in coverage for all reported compared to the previous year.

Read the data here: https://hubs.li/Q03B7r6d0

08/03/2025

In our July monthly recap, we list our top -related news items so you can stay informed in an easy-to-read and quick format.

Highlights are listed below.

Access our full recap with more FDA news here: https://hubs.ly/Q03B02X10

08/01/2025

As news headlines and social media clips reach and at a near-constant pace, primary care providers are in a pivotal position to recognize signs that a young patient may be struggling emotionally.

Elizabeth Reichert, PhD, of Stanford Department of Medicine and Stanford Parenting Center provides practical reminders and tips for spotting changes in behavior at well visits.

Watch our short interview with Reichert here: https://hubs.ly/Q03z_ZJW0

08/01/2025

Welcome to August!

Review some of our top headlines and news stories from the month of July, including the highlights listed below.

Our top stories from July: https://hubs.ly/Q03zZzfH0

08/01/2025

New data released today revealed a trend in the wrong direction for rates during the 2024-2025 school year, with a decrease in coverage for all reported compared to the previous year.

Read the data here: https://hubs.li/Q03z-K590

07/31/2025

The U.S. Food and Drug Administration approved concizumab-mtci (Alhemo; Novo Nordisk) for hemophilia A/B without inhibitors, offering once-daily subcutaneous prophylaxis that significantly reduces bleeding rates. https://hubs.li/Q03zT_qf0

07/31/2025

Earlier this month, we launched Infectious Insights, a video series hosted by our Editor-in-Chief Tina Tan, MD, FIDSA, FPIDS, FAAP of Ann & Robert H. Lurie Children's Hospital of Chicago and the Infectious Diseases Society of America.

In our first episode, Candice W Jones, MD of Orlando Health joined to discuss what has been a hectic few months surrounding infectious disease, policy, and ACIP changes, that have left no shortage of questions among primary care providers.

Find a full recap and a direct link to our first episode here, and watch as our experts break down all the changes: https://www.contemporarypediatrics.com/view/acip-changes-prompt-concern-as-pediatricians-prepare-for-fall-vaccine-season

07/31/2025

When treating classic congenital adrenal hyperplasia (CAH), can be a factor for many patients.

Recent data to consider:

FDA-approved crinecerfont (Neurocrine Biosciences) demonstrated improvements in weight-related outcomes for children with CAH when combined with glucocorticoid therapy.

In an interview with Contemporary Pediatrics, Richard Auchus, MD, PhD, of University of Michiganexplains the data and the sustained metabolic successes through 52 weeks.

07/30/2025

New areata data:

Today, AbbVie announced positive phase 3 data for upadacitinib (Rinvoq) (15 mg and 30 mg), which demonstrated that 44.6% and 54.3% of adult and patients with severe AA reached 80% or more scalp hair coverage at week 24.

Data is from the UP-AA clinical program, which used the severity of alopecia tool (SALT) as a marker for the primary outcome.

Arash Mostaghimi, MD, MPA, MPH, of Brigham and Women's Hospital and Harvard Medical School comments on the data below.

Read our full coverage and learn more about this positive, topline data for upadacitinib here: https://www.contemporarypediatrics.com/view/alopecia-areata-data-upadacitinib-demonstrates-improvements-in-scalp-hair-coverage

Contemporary Pediatrics

08/05/2025

08/05/2025

08/05/2025

08/04/2025

08/03/2025

08/01/2025

08/01/2025

08/01/2025

07/31/2025

07/31/2025

07/31/2025

07/30/2025

Address

Website

Alerts

Contact The Business

Shortcuts

Share

Category